MT2P1

Across TCGA pan-cancer cohorts, MT2P1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of MT2P1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MT2P1 RNA is repressed in tumor relative to normal tissue. In most cancer types MT2P1 is over-expressed in tumor, although a few such as LIHC and KICH show the opposite, repressed pattern.

LIHC, KICH, and COAD are the cancer types where MT2P1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MT2P1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	−3.726	<.001	9	view →
KICH	Female	All	−1.821	<.001	8	view →
COAD	All	All	−1.064	<.001	8	view →
UCEC	All	All	+0.864	.022	8	view →
CHOL	All	All	−2.682	<.001	5	view →
HNSC	Male	All	+0.905	.005	5	view →
KIRP	All	All	−1.242	<.001	4	view →
BRCA	Female	All	−0.377	.001	4	view →
LUSC	All	All	−0.526	.034	2	view →
THCA	Male	All	−0.583	.039	1	view →
LUAD	All	All	−0.485	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

MT2P1–LIHC

Open the LIHC breakdown →